Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Novo Nordisk A/S (ADR) before investing.

In this article, we go over a few key elements for understanding Novo Nordisk A/S (ADR)’s stock price such as:

• Novo Nordisk A/S (ADR)’s current stock price and volume
• Why Novo Nordisk A/S (ADR)’s stock price changed recently
• Upgrades and downgrades for NVO from analysts
• NVO’s stock price momentum as measured by its relative strength

About Novo Nordisk A/S (ADR) (NVO)

Before we jump into Novo Nordisk A/S (ADR)’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Want to learn more about Novo Nordisk A/S (ADR)’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Novo Nordisk A/S (ADR).

Novo Nordisk A/S (ADR)’s Stock Price as of Market Close

As of May 02, 2024, 4:00 PM, CST, Novo Nordisk A/S (ADR)’s stock price was $124.02.

Novo Nordisk A/S (ADR) is down 4.02% from its previous closing price of $129.21.

During the last market session, Novo Nordisk A/S (ADR)’s stock traded between $127.50 and $130.13. Currently, there are 4,426.40 million shares of Novo Nordisk A/S (ADR) stock available for purchase.

Novo Nordisk A/S (ADR)’s price-earnings (P/E) ratio is currently at 48.5, which is high compared to the Pharmaceuticals industry median of 24.8. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Novo Nordisk A/S (ADR) Stock Price History

Novo Nordisk A/S (ADR)’s (NVO) price is currently down 3.34% so far this month.

During the month of May, Novo Nordisk A/S (ADR)’s stock price has reached a high of $130.13 and a low of $123.83.

Over the last year, Novo Nordisk A/S (ADR) has hit prices as high as $138.28 and as low as $75.56. Year to date, Novo Nordisk A/S (ADR)’s stock is up 83.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Novo Nordisk A/S (ADR) Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 01, 2024, there was 1 analyst who downgraded Novo Nordisk A/S (ADR)’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Novo Nordisk A/S (ADR)’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Novo Nordisk A/S (ADR)’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Novo Nordisk A/S (ADR)’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Novo Nordisk A/S (ADR) (NVO) by visiting AAII Stock Evaluator.

Relative Price Strength of Novo Nordisk A/S (ADR)

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 01, 2024, Novo Nordisk A/S (ADR) has a weighted four-quarter relative price strength of 7.48%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how Novo Nordisk A/S (ADR) is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Novo Nordisk A/S (ADR) Stock Price: Bottom Line

As of May 2, 2024, Novo Nordisk A/S (ADR)’s stock price is $124.02, which is down 4.02% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Novo Nordisk A/S (ADR) stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.